Near total regression of diffuse brain metastases in adenocarcinoma of the lung with an EGFR exon 19 mutation: A case report and review of the literature

Case Reports in Oncology

Volumn 4, Issue 3, 2011, Pages 445-451

  Tang, Wen Hao ^a   Chen, Jia Hong ^a   Ye, Ren Hua ^a   Ho, Ching Liang ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Brain metastasis; EGFR mutation; Gefitinib; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; TECHNETIUM 99M;

ADULT; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER STAGING; CASE REPORT; EXON; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HEADACHE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CARCINOMA; MEDICAL HISTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 84855314869     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000331660     Document Type: Article

References (7)

1. Hashimoto N, Imaizumi K, Honda T, Kawabe T, Nagasaka T, Shimokata K, Hasegawa Y: Successful retreatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer 2006;53:387-390. (Pubitemid 44189562)
2. Yokouchi H, Yamakazi K, Kinoshita I, Konishi J, Asahina H, Sukoh N, Harada M, Akie K, Ogura S, Ishida T, Munakata M, Dosaka-Akita H, Isobe H, Nishimura N: Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 2007;7:51.
3. Shimato S, Mitsudomi T, Kosaka T, Yatabe Y, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii D, Yoshida J: EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol 2006;8:137-144. (Pubitemid 46542658)
4. Bearz A, Garassino I, Tiseo M, Caffo O, Soto-Parra H, Boccalon M, Talamini R, Santoro A, Bartolotti M, Murgia V, Berretta M, Tirelli U: Activity of Pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 2010;68:264-268.
5. Choong NW, Dietrich S, Seiwert TY, Tretiakova MS, Nallasura V, Davies GC, Lipkowitz S, Husain AN, Salgia R, Ma PC: Gefitinib response of erlotinib-refractory lung cancer involving meninges - role of EGFR mutation. Nature 2006;3:50-57. (Pubitemid 43108834)
6. Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, Hatooka S, Sueda T, Hida T, Yatabe Y, Mitsudomi T: Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009;4:1415-1419.
7. Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer 2009;65:80-84.